Mavrik® Latvija - latviešu - Adama

mavrik®

adama - emulsija ūdenī - tau-fluvalināts - insekticīdi

Timeline® FX Latvija - latviešu - Adama

timeline® fx

adama - emulsijas koncentrāts - florasulams + fluroksipirs + pinoksadēns - herbicīdi

COVID-19 Vaccine (inactivated, adjuvanted) Valneva Eiropas Savienība - latviešu - EMA (European Medicines Agency)

covid-19 vaccine (inactivated, adjuvanted) valneva

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vakcīnas - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Qdenga Eiropas Savienība - latviešu - EMA (European Medicines Agency)

qdenga

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - denges - vakcīnas - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.

Bimervax Eiropas Savienība - latviešu - EMA (European Medicines Agency)

bimervax

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vakcīnas - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Akeega Eiropas Savienība - latviešu - EMA (European Medicines Agency)

akeega

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatas audzējiem, kastrācija-izturīgs - antineoplastiski līdzekļi - treatment of adult patients with prostate cancer.

Orserdu Eiropas Savienība - latviešu - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - krūts audzējs - endokrīnā terapija - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Avandamet Eiropas Savienība - latviešu - EMA (European Medicines Agency)

avandamet

smithkline beecham plc - rosiglitazone, metformīns hidrohlorīds - cukura diabēts, 2. tips - cukura diabēts - avandamet ir norādīts ārstēšanas 2. tipa cukura diabēta pacientiem, jo īpaši lieko svaru, pacientiem -, kas nespēj, lai sasniegtu pietiekamu glycaemic kontrolēt to maksimāli pieļaujama, devu mutes metformīns vien. triple dobuma terapija ar sulfonilurīnvielas pamata, pacientiem ar nepietiekamu glycaemic kontroles neskatoties uz dual dobuma terapijas ar to maksimāli pieļaujama devu metformīns un sulfonilurīnvielas pamata, (skatīt 4. iedaļu.